William N. Starling is General Partner of Synergy Life Science Partners, LP (www.synergylsp.com) and Chief Executive Officer of Synecor, LLC, (Synecor) a business generator of new Life Science companies based in Research Triangle Park (RTP), North Carolina, Santa Rosa, California, and Portola Valley, California. Synecor (www.synecor.com) has significant academic, scientific, physician, venture capital, corporate, and investment banking partnerships and is focusing its efforts on the identification and development of proprietary, disruptive technologies with extraordinary market potential in the life sciences field. As CEO of Synecor, Mr. Starling is a cofounder of BaroSense, Inc., Bioerodible Vascular Solutions, Inc., (acquired by Guidant/Abbott in April 2004), InnerPulse, Inc. (formerly Interventional Rhythm Management, Inc.), and TransEnterix, Inc., the initial four companies founded and incubated by Synecor. Mr. Starling currently serves as Chairman of the Board of InnerPulse Inc., a RTP, NC - based cardiac rhythm management company, and CEO of TransEnterix, Inc., a RTP, NC - based less invasive GI Surgery company. William N. Starling received his BS degree from the University of North Carolina at Chapel Hill and his MBA degree from the University of Southern California. He began his 30 year career in the medical technology device industry at American Edwards Laboratories (Edwards LifeSciences - NYSE:EW). He was subsequently part of the founding management team and Director of Marketing for Advanced Cardiovascular Systems, Inc. (acquired by Guidant/Abbott), and was a cofounder, Vice President and Board member of Ventritex, Inc. (acquired by St. Jude Medical). In 1992, Mr. Starling was a cofounder and Chairman of the Board of Directors and President/CEO of Cardiac Pathways Corporation (acquired by Boston Scientific Corporation), and was responsible for raising significant capital from the early venture capital period through an initial public offering in 1996. Mr. Starling has been primarily responsible for raising over $300 million in private and public capital for the companies that he has co-founded and the combined revenues of these companies exceeds $2.75 billion annually. In addition to the companies that he has co-founded, Mr. Starling has made private investments in the initial equity financings of over 40 startup companies and has served/is a Board member in over 20 early stage life science companies. Mr. Starling also serves as an independent, outside Director of AMI-Semiconductor, Inc. (NASDAQ:AMIS), a key vendor for InnerPulse, Inc. Mr. Starling serves on the Board of Visitors of the Kenan-Flagler Business School and the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill and the External Advisory Board of the Stanford Stroke Center at the Stanford University Medical Center. Mr. Starling is the recipient of the BSBA Alumni Merit Award for 2006 from the Kenan-Flagler Business School